Prolate Shortage: What Providers and Prescribers Need to Know in 2026

Providers prescribing Prolate (oxycodone hydrochloride and acetaminophen, CII) in 2026 are encountering a common and frustrating pattern: patients report being turned away from multiple pharmacies. Though Prolate is not on the FDA's official drug shortage list, the structural realities of Schedule II opioid distribution make localized availability gaps persistent and widespread. This article provides clinical context and actionable strategies for providers managing this problem.

Why Prolate Is Difficult to Find: A Clinical Perspective

Prolate is manufactured by Forte Bio-Pharma LLC and contains oxycodone hydrochloride combined with a lower acetaminophen dose (300mg per tablet) than the more common 325mg found in most generics and Percocet. This lower APAP formulation is the drug's principal clinical differentiator — it can meaningfully reduce cumulative acetaminophen exposure in patients requiring multiple daily doses.

However, as a brand-name product from a smaller specialty manufacturer, Prolate is not routinely stocked at most chain pharmacies. The majority of pharmacies carry generic oxycodone/acetaminophen (325mg APAP) rather than the Prolate brand. Several systemic factors compound this:

DEA aggregate production quotas. The DEA has reduced oxycodone aggregate production quotas (APQs) multiple times since 2017. Lower APQs create tighter allocation throughout the supply chain, affecting both brand and generic products.

Distributor order monitoring and thresholds. Following the DEA's Suspicious Order Monitoring (SOM) requirements and subsequent litigation against opioid distributors, wholesale distributors have tightened their order thresholds significantly. Pharmacies that exceed these thresholds can have opioid orders blocked or delayed.

Pharmacy-level self-imposed limits. Many chain pharmacies and pharmacy benefit managers have implemented internal policies limiting the quantity of Schedule II opioids dispensed per patient or per month, in response to regulatory pressure and public health concerns.

Clinical Considerations When Prolate Is Unavailable

When a patient reports inability to fill their Prolate prescription, providers have several clinical options to consider, each with distinct implications:

1. Authorize Generic Substitution

If the prescription was written "Dispense As Written" for Prolate, modifying the prescription to allow generic substitution is the fastest solution for most patients. Generic oxycodone/acetaminophen is therapeutically equivalent and far more widely stocked. Providers should counsel patients that the APAP dose will increase from 300mg to 325mg per tablet — at 4 tablets/day this represents an additional 100mg APAP/day, well within safe limits for most patients but worth noting for those at the margin of recommended daily APAP intake.

2. Prescribe to a Different Opioid Combination

If the patient cannot tolerate or access any oxycodone/acetaminophen formulation, consider a conversion to hydrocodone/acetaminophen. Oxycodone is approximately 1.5 times more potent than hydrocodone (oral route). A patient on Prolate 5mg/300mg four times daily (20mg oxycodone/day) would typically convert to approximately 30mg hydrocodone/day. Hydrocodone/acetaminophen (Norco, Vicodin) is generally more available at pharmacies.

38,766+ patients found their medications in stock

38K+

Find Prolate In Stock Today →

3. Write to Oxycodone Alone

For patients who need oxycodone but for whom acetaminophen is not appropriate or adds little value, prescribing immediate-release oxycodone alone (generic oxycodone HCl) may be a valid option. This removes the APAP component entirely and broadens pharmacy access, though the patient will need to manage any additional non-opioid analgesia separately.

Regulatory and Documentation Obligations

Regardless of the prescribing decision, providers should ensure documentation is complete. Key points:

Schedule II prescriptions may not be refilled; each fill requires a new written or electronic prescription

If writing a prescription to accommodate a pharmacy shortage, document the clinical rationale in the chart

Ensure PDMP (Prescription Drug Monitoring Program) check is current per your state requirements

Opioid Analgesic REMS requires that providers be familiar with and comply with FDA-required education elements for opioid prescribing

Skip the calls, skip the stress.

Find Prolate In Stock Today →

50K+

Medications
Found

99%

Success
Rate

6+

Hours saved
on average

Supporting Patients in Finding Prolate

For practices with patients who frequently report difficulty locating controlled substances, consider recommending medfinder for providers. medfinder is a paid service that contacts pharmacies near a patient to identify which ones can fill their prescription. This can reduce patient callbacks to your office and reduce the risk of missed doses.

The Bottom Line for Prescribers

Prolate's availability challenges are structural and unlikely to fully resolve without systemic changes to DEA quota policy and distributor practices. Providers can best serve their patients by having a clear protocol for when Prolate is unavailable — including documented first-line alternatives, PDMP compliance procedures, and patient resources like medfinder. For a step-by-step patient support guide, see our article on how to help your patients find Prolate in stock.